TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers - A Single Institution Retrospective Analysis.

ABSTRACT:

Objective

There are limited data on the utility of TAS-102 plus bevacizumab in patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) treated in India.

Methods

Patients diagnosed with chemotherapy-refractory mCRC, defined as having received at least prior oxaliplatin and irinotecan-based chemotherapy between January 2017 and January 2022, and who began treatment with a combination of TAS-102 and bevacizumab were retrospectively analyzed for demographic variables, survivals, and prognostic parameters. The primary endpoint of the study was estimation of the median overall survival (OS) by the Kaplan-Meier method.

Results

The data of 143 patients satisfied the prespecified inclusion criteria and were included for analysis. There was a predominance of l

SUBMITTER: Joarder R 

PROVIDER: S-EPMC12714468 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature